Bikbov, Mukharram M.
Gilmanshin, Timur R.
Zainullin, Rinat M.
Kazakbaeva, Gyulli M.
Arslangareeva, Inga I.
Panda-Jonas, Songhomitra
Khikmatullin, Renat I.
Aminev, Said K.
Nuriev, Ildar F.
Zaynetdinov, Artur F.
Uzianbaeva, Yulia V.
Nikitin, Nikolay A.
Mukhamadieva, Svetlana R.
Yakupova, Dilya F.
Rakhimova, Ellina M.
Rusakova, Iulia A.
Bolshakova, Natalia I.
Safiullina, Kamila R.
Jonas, Jost B.
Funding for this research was provided by:
Projekt DEAL
Article History
Received: 21 February 2020
Accepted: 10 November 2020
First Online: 20 November 2020
Competing interests
: Jost B. Jonas: Advisory Board Novartis; Patent holder with Biocompatibles UK Ltd. (Farnham, Surrey, UK) (Title: Treatment of eye diseases using encapsulated cells encoding and secreting neuroprotective factor and/or anti-angiogenic factor; Patent Number: 20120263794), and Europäische Patentanmeldung 16 720 043.5 and Patent application US 2019 0085065 A1 “Agents for use in the therapeutic or prophylactic treatment of myopia or hyperopia); Songhomitra Panda-Jonas: Patent holder with Biocompatibles UK Ltd. (Farnham, Surrey, UK) (Title: Treatment of eye diseases using encapsulated cells encoding and secreting neuroprotective factor and/or anti-angiogenic factor; Patent No. 20120263794), and Europäische Patentanmeldung 16 720 043.5” Agents for use in the therapeutic or prophylactic treatment of myopia or hyperopia). All other authors: No financial disclosures.